Cite
NorBreast-231 trial: a randomized phase II study evaluating weekly oral vinorelbine versus weekly paclitaxel in estrogen receptor positive, HER2-negative patients with advanced breast cancer
MLA
Saverio Cinieri, et al. “NorBreast-231 Trial: A Randomized Phase II Study Evaluating Weekly Oral Vinorelbine versus Weekly Paclitaxel in Estrogen Receptor Positive, HER2-Negative Patients with Advanced Breast Cancer.” European Journal of Cancer, vol. 92, Apr. 2018, p. S98. EBSCOhost, https://doi.org/10.1016/s0959-8049(18)30523-9.
APA
Saverio Cinieri, M Groc, L. Garcia Estevez, G. Villanova, H Hervieu, Roberto Hegg, M. Ruiz Borrego, Matti Aapro, Serafin Morales, R. De Freitas Junior, Elżbieta Starosławska, & E. Szombara. (2018). NorBreast-231 trial: a randomized phase II study evaluating weekly oral vinorelbine versus weekly paclitaxel in estrogen receptor positive, HER2-negative patients with advanced breast cancer. European Journal of Cancer, 92, S98. https://doi.org/10.1016/s0959-8049(18)30523-9
Chicago
Saverio Cinieri, M Groc, L. Garcia Estevez, G. Villanova, H Hervieu, Roberto Hegg, M. Ruiz Borrego, et al. 2018. “NorBreast-231 Trial: A Randomized Phase II Study Evaluating Weekly Oral Vinorelbine versus Weekly Paclitaxel in Estrogen Receptor Positive, HER2-Negative Patients with Advanced Breast Cancer.” European Journal of Cancer 92 (April): S98. doi:10.1016/s0959-8049(18)30523-9.